SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant fibroblast growth factor receptor (FGFR) signaling drives various malignancies, particularly those with limited therapeutic options.
• FGFRs are crucial in cell proliferation, differentiation, and survival, making them attractive targets for cancer therapy.

Purpose of the Study:

• To investigate the in vitro and in vivo anticancer efficacy of SOMCL-085, a novel FGFR-dominant multi-target kinase inhibitor.
• To evaluate SOMCL-085's inhibitory effects on FGFR kinase activity and downstream signaling pathways in cancer cells.

Main Methods:

• In vitro kinase screening of SOMCL-085 against a panel of 20 tyrosine kinases.
• Assessment of SOMCL-085's effects on FGFR phosphorylation and downstream effectors (PLCγ, Erk) in cancer cell lines.
• Evaluation of SOMCL-085's anti-proliferative effects and cell cycle arrest in FGFR-aberrant cancer cell lines.
• In vivo studies using xenograft mouse models of lung and gastric cancer to assess tumor growth suppression.

Main Results:

• SOMCL-085 potently inhibited FGFR1, FGFR2, and FGFR3 kinase activity (IC50 values: 1.8, 1.9, 6.9 nmol/L).
• The compound also inhibited angiogenesis kinases VEGFR and PDGFR but showed no significant effect on 12 other tyrosine kinases.
• SOMCL-085 dose-dependently inhibited FGFR phosphorylation and downstream signaling (PLCγ, Erk) in cancer cell lines.
• It suppressed FGFR-driven cell proliferation by inducing G1/S phase arrest and significantly reduced tumor growth in vivo without affecting body weight.

Conclusions:

• SOMCL-085 is a potent multi-target FGFR inhibitor with significant anticancer activity.
• The drug effectively inhibits FGFR-dependent neoplastic phenotypes in vitro and in vivo.
• SOMCL-085 shows promise as a therapeutic agent for cancers with aberrant FGFR activation.